MedPath

江西新赣江药业股份有限公司

Ownership
-
Established
2004-04-20
Employees
-
Market Cap
-
Website
http://www.xgjyy.com

Clinical Trials

0

Active:0
Completed:0

Trial Phases

0 Phases

Drug Approvals

168

NMPA:168

Drug Approvals

Polylucose

Product Name
缩合葡萄糖
Approval Number
国药准字H36021630
Approval Date
Nov 3, 2022
NMPA

Glycine

Product Name
甘氨酸
Approval Number
国药准字H36021624
Approval Date
Nov 3, 2022
NMPA

Stanozolol

Product Name
司坦唑醇
Approval Number
国药准字H20066179
Approval Date
Nov 3, 2022
NMPA

Trochisci Piperazini Phoshatis

Product Name
磷酸哌嗪宝塔糖
Approval Number
国药准字H36022452
Approval Date
Jul 18, 2022
NMPA

Piroxicam Tablets

Product Name
吡罗昔康片
Approval Number
国药准字H36020568
Approval Date
Jul 13, 2022
NMPA

Norfloxacin Capsules

Product Name
诺氟沙星胶囊
Approval Number
国药准字H36020547
Approval Date
May 6, 2022
NMPA

Repaglinide

Approval Number
国药准字H20163343
Approval Date
Mar 9, 2022
NMPA

Metamizole Sodium Tablets

Product Name
安乃近片
Approval Number
国药准字H36020543
Approval Date
Mar 9, 2022
NMPA

Compound Diclofenac Sodium Chlorphenamine Maleate Tablets

Product Name
氯芬黄敏片
Approval Number
国药准字H36022110
Approval Date
Mar 9, 2022
NMPA

Pediatric Paracetamol,Atificial Cow-bezoar and Chlorphenamine Maleate Tablets

Product Name
小儿氨酚黄那敏片
Approval Number
国药准字H36022112
Approval Date
Feb 28, 2022
NMPA
  • Prev
  • 1
  • 2
  • 3
  • 4
  • 5
  • 17
  • Next

Clinical Trials

No trials found

News

No news found

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.